30 employees
IconOVir Bio is a preclinical-stage biotechnology company developing oncolytic virus therapy for the treatment of patients with cancer.
2018
$77M
from 8 investors over 8 rounds
IconOVir Bio raised $77M on January 5, 2021
Investors: Nextech Invest, Bellco Capital, Logos Global Management, LP, Wellington Partners, Two River, GV, Polaris Partners and Vida Ventures, LLC